Purdue Pharma Canada announces the appointment of David A. Pidduck as Vice President of Marketing & Health Solutions
PICKERING, ON, Jan. 27, 2014 /CNW/ - Purdue Pharma Canada today announced the appointment of David A. Pidduck to the position of Vice President, Marketing and Health Solutions, effective January 27, 2014. In this role, Mr. Pidduck will be responsible for leading all sales and marketing activities and will be a key member of Purdue's executive leadership team, reporting to Dr. Craig Landau, President and CEO.
Mr. Pidduck earned his MBA from the Kellogg School of Management and comes to Purdue with many years of commercial experience in the pharmaceutical, drug delivery and device industries. He spent over 25 years at Baxter, most recently as Vice President for Baxter's Medication Delivery business in Europe, based in Zurich, Switzerland. In his career at Baxter, David held multiple executive roles within the corporate and regional businesses, and led several Canadian business units. His experience spans many disciplines, including Sales, Marketing, Finance, Business Development, and Corporate Strategy.
According to Dr. Landau: "David's experience in Canada, the U.S. and Europe will provide valuable business and organizational perspectives, and will help Purdue further its position as the leading innovative analgesic pharmaceutical company in Canada. Further, David will be a key contributor to Purdue's business diversification strategy going forward, in keeping with our goal of bringing health benefits to Canadian patients through innovative products."
About Purdue Pharma Canada
Purdue Pharma (www.purdue.ca) is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.Back to Top
PURDUE PHARMA CANADA ANNOUNCEMENT
September 9, 2013
Purdue Pharma Canada is pleased to announce the appointment of Craig Landau, MD to the position of President and CEO at the beginning of September 2013. Dr. Landau will be taking over from Dr. Cornelia Hentzsch, who successfully led Purdue Canada through a challenging transition from OxyContin® to OxyNEO®. Dr. Hentzsch will become a full-time advisor to the Board of Directors and continue her role as Regional Director for Australia/New Zealand.
Dr. Landau entered the pharmaceutical industry in 1997 and has spent the last 14 years at Purdue Pharma (U.S.), headquartered in Stamford, Connecticut. In his most recent role as Chief Medical Officer and Vice President of R&D Innovation, Clinical and Medical Affairs, he led a number of successful clinical development initiatives resulting in analgesic product registrations in the U.S., Europe, and other regions. Through an R&D Innovation function, Dr. Landau has been responsible for pursuing non-drug based technologies and biomarkers intended to bring additional objectivity to the diagnosis and management of pain and the pain patient. Through April 2013, he played a lead role in the development and approval of reformulated OxyContin, a product recently determined by the U.S. Food and Drug Administration to possess abuse deterrent characteristics.
Dr. Landau earned his BSc degree in Physiology and Anatomy from Cornell University, and his MD degree from Mount Sinai School of Medicine. He completed his Anesthesiology residency at Yale University, with specialty training in chronic pain management, obstetric and peripheral vascular anesthesia. A U.S. Army Veteran, in 2004 he completed a distinguished 12-year career in the U.S. Army Medical Corps, Reserve Component, providing clinical anesthesia and pain management care to soldiers at a combat support hospital in support of American forces in Iraq and Afghanistan.Back to Top
PURDUE PHARMA CANADA STATEMENT ON GENERIC OXYCONTIN®
November 19, 2012
Purdue Pharma Canada is deeply concerned with today's statement from the federal Minister of Health that she may not act to delay a decision on generic OxyContin.
The Minister states that she has heard from doctors and patients about OxyContin's positive impact on the treatment of severe pain and that the issue of prescription drug abuse is larger than one specific product. We agree. But the Minister's own Scientific Advisory Panel recommended in March 2011 that manufacturers introduce new opioids which are less crushable and less abusable. This is why we introduced OxyNEO®.
The Minister refers to "insufficient proof" to back up claims that OxyNEO, the replacement for OxyContin, is harder to abuse. We disagree. In fact, published data from surveillance studies in the U.S., where OxyNEO has been available for two years, has been submitted on a regular basis and the most recent data submission is still under review by Health Canada.
It shows significant decline in abuse and demand, including a lower street price for the tablets as well as decreases in admissions to addiction treatment and the number of adverse drug reactions reported to poison control centres. There is also evidence of improved safety for patients and their caregivers. We are disappointed that Health Canada has not taken this important evidence into account.
The Minister indicates the law does not permit her to withhold approval. On the contrary, under the Food and Drugs Act, the Minister must be satisfied that any drug, including generics, meets safety and effectiveness standards prior to issuing an approval.
A higher standard has been established with OxyNEO and it is one that should now be applied to all new controlled-release oxycodone products, including generics. As such, we urge the Minister to consider the evidence and require any generic OxyContin to meet those standards in the interest of public and patient safety.
About Purdue Pharma Canada
A research-based pharmaceutical company in Pickering, Ontario, Purdue Pharma Canada (www.purdue.ca) is committed to improving patient health and well-being, by developing innovative medicines and supporting quality education for the safe use of its products.Back to Top
PURDUE PHARMA CANADA STATEMENT ON THE INTRODUCTION OF OXYNEO AS A REPLACEMENT FOR OXYCONTIN
February 27, 2012
Purdue Pharma has been working with health authorities for almost two years to prepare the way for the introduction of OxyNEO as a replacement for OxyContin across Canada. We are aiming to ensure as smooth a transition as possible, after which OxyContin will be discontinued and replaced with OxyNEO.
OxyNEO tablets provide the pain relief of OxyContin. But OxyNEO tablets have different properties. They have been hardened to reduce the risk of being broken, crushed or chewed. The tablets also become gel-like when in contact with water.
The restrictions to OxyNEO funding being imposed by some provinces are surprising. This product was specifically designed to help discourage misuse and abuse of the medication. Health Canada’s Special Advisory Panel recommended that manufacturers introduce new opioids which are less crushable and less abusable. OxyNEO is the first of such products on the market and paradoxically it now faces significant restrictions for new patients in most provinces. Patients currently being treated with OxyContin will be “grandfathered” for varying periods of time, which means they will be allowed to continue therapy with OxyNEO if their physician decides this is appropriate.
Purdue Canada does not claim that OxyNEO will prevent all tampering for the purpose of drug diversion, misuse and abuse. However, it is a step in the right direction. Purdue Canada supports restrictions for strong opioids in accordance with the Canadian Guideline for Opioid Use for Chronic Pain as well as careful patient selection. But we are deeply concerned that decisions to limit access to OxyNEO will compromise optimal patient care.
About Purdue Pharma Canada
A research-based pharmaceutical company in Pickering, Ontario, Purdue Pharma (Canada) (www.purdue.ca) is committed to improving patient health and well-being, by developing innovative medicines and supporting quality education for the safe use of its products. Purdue is a recognized leader in research and development of products for the treatment of pain. Its portfolio of products also includes medication for the treatment of attention deficit hyperactivity disorder (ADHD), respiratory disease, gastrointestinal disorders and infection control.Back to Top
UOIT announces $25,000 donation from Purdue Pharma
March 6, 2009
Announcement made during second annual Purdue Pharma Distinguished Lecture OSHAWA, ON. - The University of Ontario Institute of Technology's (UOIT) Faculty of Science hosted its second annual Purdue Pharma Distinguished Lecture on campus yesterday and, in conjunction with the event, Purdue announced it has made a $25,000 donation to create an endowment to support UOIT science students.
The donation, which is being matched by the Ontario Trust for Student Support for a total value of $50,000, will be used toward the creation of an endowment that will generate one $2000 award each year. The Purdue Pharma Award will be given to a student pursuing a Bachelor of Science degree with a specialization in Pharmaceutical Chemistry, with preference given to a student who has completed the requirements for six semesters of the program and is enrolled in fourth year.
"On behalf of all the students in the Faculty of Science, I would like to thank Purdue Pharma for this significant contribution, “said Dr. William Smith, dean of the UOIT Faculty of Science. "This generous donation will help relieve the financial demands experienced by students as they continue to pursue a career in the pharmaceutical chemistry field by providing access to UOIT's technology-enhanced learning environment, state-of-the-art labs and world-class professors."
The lecture was delivered by Dr. Timothy Geary, Tier I Canada Research Chair in Parasite Biotechnology at McGill University. Presenting Why Parasites Matter, Dr. Geary spoke to students and community members on a variety of topics including the effect that parasites have on their hosts and potential therapeutic exploitation.
The Purdue Pharma Distinguished Lecture is designed to expose students and the general public to some of the country's leading experts and researchers as they explore a broad range of research topics related to the health of Canadians.
The support of leading corporations such as Purdue Pharma helps enhance the innovative and exceptional educational experience offered to students at UOIT. In particular, it furthers the Faculty of Science's dedication to creating and sharing scientific knowledge and infusing the thrill of discovery in its students, preparing them for rewarding careers as the next generation of highly skilled scientists and professionals or for post-degree studies and graduate school.
As an innovative university, UOIT delivers a leading-edge learning environment that uniquely combines academic knowledge, research opportunities, hands-on skills and a vibrant student life. UOIT's more than 5,500 students are taught by professors who are experts in their fields from around the world. As Ontario's first laptop-based university, the university offers a diverse array of challenging undergraduate and graduate degree programs through its faculties of Business and Information Technology; Criminology, Justice and Policy Studies; Education; Energy Systems and Nuclear Science; Engineering and Applied Science; Health Sciences; and Science. UOIT's commitment to research excellence has resulted in millions of dollars in grants and awards, including five Canada Research Chairs. To find out more, visit www.uoit.ca or call 905.721.8668.
Purdue Pharma joins forces with the Institute of Neurosciences, Mental Health and Addiction
Institute of Neurosciences, Mental Health and Addiction (INMHA) is pleased to announce a new partnership with Purdue Pharma to conduct research into the non-medical (illicit) use of prescription drugs with psychotropic properties - a growing public health problem in Canada.
Purdue is a research-based pharmaceutical company in Pickering, Ontario dedicated to advancing healthcare through research, education and pharmaceutical innovation. As one of several manufacturers in Canada of controlled prescription medications for the treatment of chronic pain, Purdue is concerned about the misuse and abuse of prescription drugs and is interested in funding the program for an understanding of the current prevalence and nature of prescription drug abuse. Privately held, Purdue Pharma is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.
Through this collaboration, CIHR will support research that collects and analyzes data on the epidemiology of prescription opioid abuse in Canada as well as research that identifies appropriate and effective interventions to reduce abuse and its adverse consequences.
Purdue Pharma was named the Canadian Pharmaceutical Distribution Network, or CPDN’s 2007-2008 Manufacturer of the Year (MOYA), in recognition of Purdue’s superior performance as a supplier to CPDN member hospitals. Faced with touch competition from more than 20 leading pharmaceutical companies in Canada, Purdue stood out in areas including inventory replenishment, backorder management, pricing information and catalogue maintenance.
“Earning this award demonstrated Purdue’s commitment in achieving supply chain excellence and is a direct result of concerted effort on the part of the Purdue Pharma team,” said Brian Lockwood, Vice President, Finance, Purdue Pharma.
By Mike Johnston
Oshawa-Whitby-Clarington This Week
Fri 09 Feb 2007
DURHAM -- There were smiles and applause all around as volunteers and supporters of the Ajax-Pickering-Uxbridge United Way celebrated the completion of a successful campaign Thursday night.
Purdue Pharma, a long-time supporter of United Way, also received a Corporate Citizenship Award for its lifetime achievement total of $500,000.
"We have had a very successful year. We are excited about our 2006 campaign achievement and we are thankful to all our supporters for their efforts in helping us reach our goal," noted Edna Klazek, chief executive officer of the United Way.
Read the entire story from The Pickering News Advertiser
Denver, Colorado, October 22, 2007 - In a ceremony today at the APICS 2007 International Conference and Exposition in Denver, Colorado, APICS--The Association for Operations Management awarded Smart Software, Inc. and Purdue Pharma Canada the 2007 APICS Technology Partnership Award of Excellence.
The APICS Corporate Awards of Excellence is an annual competition that recognizes companies for significant contributions and performance excellence in the field of operations management. The Technology Partnership Award recognizes a partnership between a technology solutions provider and a corporate customer, where the product noticeably increased the customer's success. Entries are judged on the originality of the solution and the way it was developed, its usefulness to the customer and the ability to deliver results, supplier performance in creatively and effectively solving the customer's problems, and the expected future impact of the technology solution.
Purdue Pharma Canada has been a Smart Software customer for a number of years. In 2005, Purdue Pharma and Smart Software partnered to improve the way the pharmaceutical company did its sales and inventory planning. At that time, Purdue Pharma upgraded its Smart Software forecasting solution to SmartForecasts® Enterprise, Smart's flagship product for demand forecasting, planning and inventory optimization. In addition, Smart and its systems integration consultant, Datamorphics, Inc. of Concord, Mass., worked with Purdue's IT, materials planning, and marketing teams to design a way to interface with Purdue Pharma's new J.D. Edwards ERP system that complied with specific data security requirements while providing improved planning and marketing information through a set of customized business intelligence reports.
After Purdue Pharma went live with the finished SmartForecasts system in June 2006, the company was able to increase service levels and reduce inventory. In addition, Purdue's planning and forecasting process became more efficient because of the special interfaces the integration team designed and built, and Purdue's ability to generate and use important planning information has improved substantially because of the custom reports that were also developed.
"Receiving this award is an important milestone in our long-standing relationship with Smart Software," said John Stewart, President and CEO, of Purdue Pharma Canada. "The project we implemented with them has improved our inventory management and the way we make stocking decisions, as well as improve the efficiency of our operations. SmartForecasts continues to produce outstanding results."
"This project was a true partnership with our valued customer, Purdue Pharma Canada," said Charles Smart, President and CEO of Smart Software. "We're pleased to have been able to work with them to improve their planning operations in a way that has achieved so many positive results. The APICS award is icing on the cake."
SmartForecasts Enterprise is a cross-industry solution for demand forecasting, demand planning, and inventory optimization that utilizes pioneering innovations, such as Smart Software's patented technology for forecasting intermittent, or "slow-moving", demand. This unique technology is being used by scores of companies with service parts operations, as well as capital goods manufacturers in a variety of industries. SmartForecasts also leverages customers' existing IT investments and reduces total cost of ownership by integrating easily with host databases, as well as ERP and SCM systems like Epicor, JD Edwards, and SAP.
Purdue Pharma is a leading manufacturer of prescription medicines for the treatment of persistent pain. Its Pickering headquarters include an R&D Formulation Laboratory, manufacturing plant, and administrative offices, employing 288 people. The company has been recognized as one of the “Top 100” employers in Canada, and celebrated its 50th anniversary in June 2006. More...
Dec 7. 2006
London, ON – Pharmaceutical company Purdue Pharma has recently awarded $200,000 in an unrestricted grant to the MD Pain Clinic at St. Joseph’s Hospital. The grant will be used to help shorten wait times and to improve patient outcomes at the clinic.
For over a decade, the pain management program at St. Joseph’s has been providing diagnosis and treatment of chronic non-cancer pain, allowing individuals with persistent pain to receive a treatment program they can follow with the help of their family doctor.
This grant will help support the clinic’s need of an additional psychologist, a primary care physician, a registered nurse, a neuropathic pain fellow and clerical staff. Ultimately the clinic hopes to establish a database of patient demographics, treatments and outcomes that will help secure long-term funding from the Ministry of Health and Long-Term Care
Long-term funding support combined with the funds from Purdue Pharma will help to educate primary care physicians in the proper treatment of chronic pain management, which will eventually lead to improved pain management at the primary care level.
Patients at Rouge Valley Ajax and Pickering to benefit.
Purdue Pharma's Executive Vice President and General Manager John Stewart expanded health care services in the Rouge Valley Ajax and Pickering area on April 25, 2002 with the donation of $300,000 to create the new Purdue Pharma Ambulatory Care Services Centre.
The donation is part of the Rouge Valley Health System's $34 million Vital Links Campaign to fund the Health System's expansion and redevelopment.
"As a leading research-based pharmaceutical company, we share a common goal with health care practitioners - to better the quality of life for patients," said Mr. Stewart. "We must invest in community-based hospitals to ensure that our community grows stronger as it grows larger."
Noting that more and more patients "are coming through our doors," Bruce Cliff, chief operating officer, Rouge Valley Ajax and Pickering said: "It makes everyone's job so much easier when we have the necessary space and tools to get the job done, and that's what makes the support from the community-and gifts like the one we received today from Purdue Pharma-so vital."
The new Purdue Pharma Ambulatory Care Services Centre will be designed to include a multipurpose clinical area that will house examination, treatment and minor surgical procedure rooms, a medical day care and recovery area, a preadmission unit where patients will be assessed and counseled prior to admission for inpatient surgery and a health education area.
Toronto, Ontario - February 12, 2004 - The Executive Vice President and General Manager of Purdue Pharma announced today his company is taking a leading role in implementing key recommendations of Newfoundland and Labrador's Task Force on the prevention of abuse of OxyContin® and other opioid analgesics. More...
Toronto, Ontario --- December 2, 2004 - The pharmaceutical company that manufactures OxyContin has partnered with one of Canada's leading hospitals to continue its battle against prescription drug abuse. Purdue Pharma and Toronto's Mount Sinai Hospital have joined forces to establish the Mount Sinai/Purdue Pharma Partnership in Pain and Dependency. More...
April 25, 2003. Purdue Pharma's Kim Cudhea, Territory Manager for Eastern New Brunswick, received the Champion Award from the New Brunswick Hospice Palliative Care Association (NBHPCA). Dr. Sydney Grant, President of the NBHPCA and Sandy Johnson, Secretary & Communications Chair, presented the award during the association's Annual Meeting and Education Day. Purdue is the first pharmaceutical company to receive the Champion Award, which recognizes individuals, groups and companies for exemplary contributions to hospice palliative care in New Brunswick.
The NBHPCA membership has increased 147% in the last two years resulting in their highest levels of education initiatives. Purdue's support contributes to a quarterly newsletter with a section devoted to case studies in pain management, education meetings, speaker sponsorship and executive planning meetings.
Sandy Johnson honoured Kim Cudhea with recognition for her ongoing work and support with the association. She thanked Kim for her efforts in organizational and planning assistance, fuelled by a passion for better pain management for cancer pain sufferers.
Thank You to PURDUE PHARMA
April 2002. Thanks to the financial support of Purdue Pharma, we are able to produce and mail our newsletter. We are grateful for their ongoing interest in Hospice Durham. We are able also, through Purdue Pharma, to use this case study, which outlines the current philosophy of pain in our clients. In the Volunteer Training Course we try to give our volunteers the basic knowledge of pain management but this case study of a real person with real pain will help to emphasize our teaching.